Free Trial
NASDAQ:EPIX

ESSA Pharma Q4 2024 Earnings Report

ESSA Pharma logo
$1.74 +0.02 (+0.87%)
As of 12:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ESSA Pharma EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

ESSA Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ESSA Pharma Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, December 17, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

ESSA Pharma's Q2 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Friday, May 16, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ESSA Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ESSA Pharma and other key companies, straight to your email.

About ESSA Pharma

ESSA Pharma (NASDAQ:EPIX), a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

View ESSA Pharma Profile

More Earnings Resources from MarketBeat